15 June 2020 - Deborah Wilkes
Archived
South Korean biopharmaceutical company Celltrion is acquiring a portfolio of prescription and OTC brands from Japan’s Takeda in a deal worth up to USD278 million.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.